Ascorbate
ApprovedSmall molecule
Ascorbate is one of 176 small molecule programs targeting Oxidative Stress. It is currently in Approved.
5
Indications
11
Total Trials
3
Active Trials
175
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1063 competitors in Pancreatic Cancer
#DrugCompanyPhaseTrials
1Ascorbate
FFudan University
Approved
Gemzar
GGynecologic Oncology Group
Preclinical
Medrol
PfizerPreclinical
Byetta
AstraZenecaPreclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Thiazolidinediones
SanofiPreclinical
Alpha-Glucosidase Inhibitors
SanofiPreclinical
Meglitinides
SanofiPreclinical
Active Comparator
ModernaPreclinical
LDE225
NovartisPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Pancreatic Cancer4 trials
A Clinical Trial Evaluating the Effect of Pharmacological Ascorbate on Radiation Therapy for Pancreatic Cancer Patients
Withdrawn·—·Phase 2·NCT03541486
Gemcitabine3 trials
Gemcitabine Plus Ascorbate for Sarcoma in Adults
Terminated·—·Phase 2·NCT03468075·10 enrolled
Glioblastoma Multiforme1 trial
A Phase I Trial of High-Dose Ascorbate in Glioblastoma Multiforme
Completed·—·Phase 1·NCT01752491·13 enrolled
Oxidative Stress1 trial
1 more indication
Schizophrenia1 trial
Treatment of Acute Schizophrenia With Vitamin Therapy
Completed·—·Phase 4·NCT00140166·55 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ascorbate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- FFudan University